

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团

Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

PROFIT WARNING

This announcement is made by Meilleure Health International Industry Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Company, the Group expects to record a profit attributable to the Shareholders of approximately HK\$10.6 million for the six months ended 30 June 2022 as compared to a profit attributable to the Shareholders of approximately HK\$43.2 million for the six months ended 30 June 2021. Such expected decrease is mainly due to the following reasons:

- (i) a significant unrealised decline in fair values on investments at fair value through profit or loss as a result of adverse market conditions;
- (ii) a decrease in segment profit from agency service and trading business as a result of the overall downturn in the real estate market of mainland China;
- (iii) a decrease in segment profit from industrial hemp business as a result of the prohibition of the use of industrial hemp in all cosmetics in mainland China;
- (iv) the absence of the one-off significant gain on deemed partial disposal of investment in a joint venture recorded during the six months ended 30 June 2021;
- (v) a material decline in revaluation gain of investment properties of the Group. This is mainly because of the slowing-down economic growth in mainland China resulting from the outbreak of 2019 novel coronavirus disease; net off with

- (vi) an increase in segment profit from healthcare-related business, which mainly benefited from the sale of skincare products under the Group’s brand “Jixiaojian” launched in the second half of the year 2021.

The information contained in this announcement is only based on a preliminary assessment by the Board according to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and the information available to the Board as at the date of this announcement, which have not been reviewed, confirmed or audited by the Company’s auditors and/or the audit committee and are subject to adjustment. The Company is in the process of preparing and finalising the Group’s interim results for the six months ended 30 June 2022. Details of the Group’s financial information for the six months ended 30 June 2022 will be disclosed in its interim results announcement which is expected to be published on or before 31 August 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 9 August 2022

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Mr. Wu Peng as independent non-executive Directors.